IAS 2011: Once-daily Elvitegravir Matches Twice-daily Raltegravir
- Details
- Category: Experimental HIV Drugs
- Published on Wednesday, 20 July 2011 00:00
- Written by Liz Highleyman
The experimental HIV integrase inhibitor elvitegravir works as well as raltegravir (Isentress) for treatment-experienced people with extensive drug resistance, and was well-tolerated overall, according to data presented at the International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2011) this week in Rome. 
IAS 2011: The Proof is Here: HIV Treatment is HIV Prevention
- Details
- Category: Treatment as Prevention
- Published on Tuesday, 19 July 2011 00:00
- Written by Paul Dalton
Antiretroviral treatment was shown to prevent HIV infection in the large, randomized trial HPTN 052 trial, reducing risk by 96%, researchers reported at IAS 2011 this week in Rome.
"There is a clinical benefit for the patient and a dramatic, nearly 100% reduction in transmission," said lead investigator Myron Cohen. "We can't get much better." 
IAS 2011: Stakeholders Call for HIV Cure Research
- Details
- Category: Search for a Cure
- Published on Tuesday, 19 July 2011 00:00
- Written by IAS
Over the past few years a cure for HIV has again become a goal of HIV/AIDS research. The International AIDS Society is a leading proponent of greater investment in cure-related science. 
IAS 2011: Coronary Artery Calcification Linked to Bone Loss
- Details
- Category: Cardiovascular Disease
- Published on Tuesday, 19 July 2011 00:00
- Written by Paul Dalton
Coronary artery calcification is associated with and low femoral bone mineral density (BMD), but no such link found with lumbar spine BMD, researchers reported at IAS 2011 in Rome.
IAS 2011: HIV Treatment as Prevention: HPTN 052 Offers Proof [VIDEO]
- Details
- Category: Treatment as Prevention
- Published on Tuesday, 19 July 2011 00:00
- Written by Gregory Fowler
HPTN 052 lead investigator Myron Cohen talked to Paul Dalton from HIVandHepatitis.com about the study's findings and their significance. 
More Articles...
- IAS 2011: Changing Face of HIV Vaccine Research [VIDEO]
- IAS 2011: Transplants Safe for HIV+ People but HCV Adds Risk
- IAS 2011: Studies Confirm PrEP, Early ART Prevent HIV Transmission [VIDEO]
- IAS 2011: Universal Access to Science [VIDEO]
- IAS 2011: Biomedical Prevention a Watershed, Global Access Remains Elusive
- IAS 2011: AIDS is at a Scientific Watershed [VIDEO]
- IAS 2011: Expand Treatment for Prevention, Experts Urge
- IAS 2011: New Studies Add Evidence that PrEP Reduces HIV Infection Risk
- IAS 2011 Will Explore Diverse Aspects of HIV/AIDS
Web Design and Development by